Egypt cancer Network sponsors study for a new 57357 research Institute within the Hospital’s future expansion
Consultant Hesham Dinana, author of the study:”Without Hospital 57357’s expansion program, performance and leadership are threatened to decline”
I had the pleasure of chatting with Dr. Hesham Dinana, VP of a prominent management consulting firm, Solving Efeso Egypt, who just handed in a feasibility study regarding the establishment of a new research Institute for Hospital 57357. The study was funded by 57357′s non-profit affiliate in the U.S., Egypt Cancer Network. Hospital 57357′s present research department, situated on the third floor of the actual 57357 building, is in need of more space, infrastructure and equipment for it to expand.
Dr. Dinana, you go along away with Hospital 57357, you were there at the very beginning, at the inception of the project?
This is correct; I was working at Philips Medical System in North America in 1999 when board members of the Association of the Friends of the National Cancer Institute, AFNCI offered me to be the project manager of Hospital 57357 on behalf of the Association. This was a challenging experience overseeing and coordinating the different establishment phases of this unique project.
You have already been involved with three feasibility studies with respect to the up-coming 57357 expansion program, namely the Health Sciences Academy, the research Institute, and the introduction of a new therapy, the proton therapy, what is your appreciation for this vast expansion program including the new green Leed 300 bed tower?
Within almost 6 years of operation, Hospital 57357‘s quality performance has been growing steadily with patients outcomes and cure rates approaching those of the developed nations. Presently, over-all survival rates record an average of 70% at 57357 while in the developed countries the present rate is 80 to 85%. This steady growth has reached a plateau from which the Hospital is required to move upward through its expansion program in order for this healthcare center to resume its pursuit of excellence, quality and leadership in the region.
Let me explain this in simple words: In order for the Hospital to succeed in its mission of challenging the frontiers of cure, it has to work on two main fronts: first, offering more children with cancer the opportunity of cure, hence expanding its present capacity. Second, improving the outcome of its patients through the improvement of treatment methods and protocols regarding their suitability to the environmental, biological and racial conditions in the region, hence a greater involvement in research, and through the introduction of new therapies.
You have just handed in a feasibility study on the establishment of a 57357 research institute. What were the main results of your study?
The establishment of the research center is crucial for the Hospital as I already mentioned in order for it to maintain growth, excellence, quality, leadership and trustworthiness in the delivery of its free healthcare services. Unlike the Health Sciences Academy which does not require any capital investment, the research center will certainly need more fundraising efforts at the beginning, but after some time, it could be generating revenue as it would be able to patent its findings and share them with other hospitals and centers.
As cancer burden is expected to increase to 70% by 2020 in the developing countries and the possibility that cancer data from the west would not apply to the MENA region, Hospital 57357 could play an important role in research as it is already engaged in this path and being the largest children’s cancer hospital worldwide, benefits from following up on large population samples. For example, Hospital 57357′s data reveal that ratio of incidences of Lymphomas versus Leukemia is 1: 1.5 while this same ratio in the developed countries is 1: 4. Working on identifying the reasons for such differences is valuable for this part of the world.
Moreover, the study shows that there might be a change in perception of Egyptians towards research. They seem to be realizing more its importance in finding breakthroughs to their problems and are more willing to donate money for it. It is noteworthy that in 2009, 19billion $ were invested on cancer research globally , 78% of which was spent on non-commercial research. U.S. and Europe account for more than 60% of the spending on non-commercial research. Furthermore, cancer biology and cancer treatment are the areas receiving the highest level of cancer research expenditure globally. In contrast, Egypt is ranked by the RAND Document (2003) as ‘scientific developing’, which means that they are making some investments in cancer research, but are still well below international standards.
Presently, Hospital 57357 is embarking on a vast expansion program for the sake of not having to turn away any child seeking its free quality services as its capacity is stretched to the maximum. The program includes an up-coming 60 bed extension within its premises, a 300 bed green LEED tower to be joined to the main Hospital, a Health Sciences training Academy housing the new research Institute, and the introduction of a new therapy technology, the proton therapy.
Egypt Cancer Network 57357 and AFNCI is a U.S. based non-profit 501C3 to which all donations are tax deductible. ECN is committed to provide resources to Egyptian Hospitals and non profit organizations focused on cancer in the areas of patient care, scientific advancement and education